Sandoz Picks Up Pfizer's Infliximab Biosimilar

Novartis AG's generics business Sandoz is bulking up its budding biosimilars portfolio by acquiring the rights to Pfizer Inc.'s PF-06438179, a biosimilar version of infliximab (Johnson and Johnson's Remicade), in Europe.